N-[3-(5H-dibenzo[a, d]cyclohepten-5-ylidene)propyl]-N-methylamino- (6a) and N-[3-(6H-dibenz-[b, e]oxepin-11-ylidene)propyl]-N-methylamino-alkanoic acid derivatives (6b) and related compounds (6c-f) were synthesized and examined for pharmacological activities in vitro, i.e., inhibitory effect on monoamine [noradrenaline (NA) and 5-hydroxytryptamine (5-HT)] uptake, inhibitory effect on 5-HT-, histamine-, acetylcholine-
一系列N- [3-(5H-二苯并[a,d]环庚-5-亚烷基)丙基] -N-甲基
氨基-(6a)和N- [3-(6H-dibenz- [b,e]]合成了-11-亚丙基)丙基] -N-甲基
氨基-链烷酸衍
生物(6b)和相关化合物(6c-f),并研究了其在体外的药理活性,即对单胺[
去甲肾上腺素(NA)和5-羟
色胺(5-HT)]的吸收,对5-HT,
组胺,
乙酰胆碱和NA诱导的收缩的抑制作用以及对α2
肾上腺素受体和
多巴胺D2受体的结合亲和力。体外试验表明,两性离子化能够维持H1抗
组胺活性,同时大大降低其他药理活性。此外,6a-f对化合物48/80诱导的大鼠致死性的抑制作用比相应的N,N-
二甲基胺(2a-f)强得多。